Home/Pipeline/NPM1 One-Step MRD Kit

NPM1 One-Step MRD Kit

Acute Myeloid Leukemia (AML)

RUOActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

RUO

Status

Active

Company

EntroGen

About EntroGen

EntroGen is a privately held, commercial-stage diagnostics company founded in 2008 and headquartered in Woodland Hills, California. The company has established a commercial footprint with its FDA-approved companion diagnostic for KRAS/NRAS mutations in colorectal cancer and is expanding its portfolio with RUO kits for minimal residual disease (MRD) and microsatellite instability (MSI). EntroGen's strategy centers on providing end-to-end, automated molecular diagnostic solutions to support personalized treatment decisions in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active